TY - JOUR
A2 - Abdel-Dayem, H.
A2 - Smith, T.
A2 - Kao, C.-H.
AU - Cistaro, Angelina
AU - Quartuccio, Natale
AU - Mojtahedi, Alireza
AU - Fania, Piercarlo
AU - Filosso, Pier Luigi
AU - Cucinotta, Mariapaola
AU - Campennì, Alfredo
AU - Ficola, Umberto
AU - Baldari, Sergio
PY - 2013
DA - 2013/10/09
TI - Is %ΔSUVmax a Useful Indicator of Survival in Patients with Advanced Nonsmall-Cell Lung Cancer?
SP - 910957
VL - 2013
AB - Purpose. To investigate the impact of the maximum standardized uptake value (SUVmax), size of primary lung lesion, and %ΔSUVmax on outcome (overall survival (OS) and 2-year disease-free survival (2-year DFS)) of patients with advanced nonsmall-cell lung cancer (NSCLC). Materials and Methods. 86 stage III-IV NSCLC patients underwent 18 F-FDGPET/CT, before and after chemotherapy, and were classified into subgroups according to the response criteria of the European Organization for Research and Treatment of Cancer. SUVmax values and tumor size with the best prognostic significance were searched. Correlation between the SUVmax value and the initial response to therapy (best response) and the relationship between %ΔSUVmax and OS were assessed. Results. In patients in PD (20/86), the average pretreatment SUVmax was 11.8±5.23, and the mean size of the primary lesion was 43.35 mm±16.63. In SD, PR, and CR patients (66/86), the average pretreatment SUVmax was 12.7±8.05, and the mean size of the primary lesion was 41.6 mm±21.15. Correlation was identified only for %ΔSUVmax; patients with PD (ΔSUVmax > +25%) showed a worse OS than patients with ΔSUVmax < +25% (CR, PR, and SD) (P=0.0235). Conclusions. In stage III-IV NSCLC, among the assessed factors, only %ΔSUVmax may be considered as a useful prognostic factor.
SN - 2356-6140
UR - https://doi.org/10.1155/2013/910957
DO - 10.1155/2013/910957
JF - The Scientific World Journal
PB - Hindawi Publishing Corporation
KW -
ER -